<DOC>
	<DOCNO>NCT01266785</DOCNO>
	<brief_summary>Crohn 's disease inflammatory ( swell soreness ) disorder digestive tract . Affected patient suffer abdominal pain , diarrhea ( sometimes bloody ) , weight loss . It lifelong disease frequent flare course disease . Crohn 's disease mostly treat medication , sometimes surgery need . Infliximab medication treat severe Crohn 's disease . This medicine effective block special substance ( tumor necrosis factor ) release certain white blood cell body . Infliximab give via vessel week 0 , 2 , 6 initially , every 2 monthly maintenance . However , patient Crohn 's disease respond infliximab . Currently test reveal patient respond treatment . This study aim analyze compare particular subgroup white cell product infliximab treatment may determine responsiveness infliximab treatment .</brief_summary>
	<brief_title>Infliximab , Regulatory T Cells , IL2 Crohn 's Disease</brief_title>
	<detailed_description>All patient chest x-ray pregnancy test ( female ) prior infliximab treatment . There total 5 study visit . At visit , body weight measure , abdominal exam perform , 2 tablespoonful blood drawn , stool collect , questionnaire complete .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Newly diagnose exacerbate CD ( Moderate severe CD ) . The diagnosis moderate severe CD confirm previous endoscopy biopsy . Have capacity understand sign inform consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>crohn 's</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Inflammatory bowel disease</keyword>
	<keyword>digestive tract</keyword>
	<keyword>Interleukin</keyword>
</DOC>